COMPASS Pathways plc

What they do

Compass Pathways is a biotechnology company focused on developing COMP360, its proprietary pharmaceutical-grade psilocybin formulation, for serious mental health conditions. The lead program is treatment-resistant depression (TRD), with a Phase 3 program completed and a rolling NDA submission underway. The company also has a Phase 2 study in PTSD and is preparing for commercial launch if approved.

Revenue drivers

• COMP360 in TRD (if approved) — The company has no approved products or revenue; potential revenue depends on FDA approval and launch. Management estimates ~4 million TRD patients in the US and expects COMP360 to be a 'blockbuster opportunity' if approved.
• COMP360 in PTSD (if developed) — Early-stage program with an open-label Phase 2 study, but no revenue expected in the near term.

Recent performance

For 2025, net loss was $269.8 million (EPS -$3.08) versus $155.1 million in 2024, driven by R&D and warrant valuation changes. Operating cash flow was -$157.2 million in 2025. As of June 30, 2026, cash and equivalents were $433.3 million, with shareholder equity of $84.5 million and long-term debt of $50.7 million. In February 2026, the COMP006 trial met its primary endpoint (MADRS change -3.8 at week 6), and in April 2026 the FDA granted a National Priority Voucher for COMP360 in TRD.

Strategy

Compass is focused on completing the rolling NDA submission for COMP360 in TRD, planned for Q4 2026, and preparing for a commercial launch in H1 2027. The company emphasizes differentiating COMP360 with rapid onset, durable response, and infrequent dosing (a few treatments per year). It is also advancing a late-stage PTSD trial and expanding commercial readiness and manufacturing capacity.

Risks

• No revenue and ongoing losses — The company has not generated any product revenue and expects to incur losses for the foreseeable future; accumulated deficit was $822.6 million as of December 31, 2025.
• Regulatory and approval risk — FDA approval of COMP360 is not guaranteed; the rolling NDA submission and Priority Voucher do not ensure approval, and the FDA may require additional data or reject the application.
• Reliance on a single product — COMP360 is the only clinical asset; any clinical, manufacturing, or regulatory setback could materially harm the business.
• Clinical trial and safety unknowns — Long-term safety and durability data are still being generated; Part C of COMP005 and other follow-ups are ongoing, and unexpected adverse events may emerge.

Outlook

Management expects to complete the NDA submission in Q4 2026 and launch COMP360 in H1 2027, if approved. With $433 million in cash, the company says it is funded well beyond launch into 2028. Key near-term milestones include ongoing rolling review discussions with the FDA and the late-stage PTSD trial.